Di Lijun

Professional Biography

Dr. Di Lijun is Chief Physician in Breast Medical Oncology at Peking University Cancer Hospital, Beijing. Clinical expertise includes Breast cancer (all subtypes), HER2-positive and HER2-low breast cancer, Triple-negative breast cancer (TNBC), HR+/HER2- metastatic breast cancer. Led the first Chinese randomized Phase II trial comparing 3-week vs. 4-week nab-paclitaxel dosing schedules in metastatic breast cancer (HER2-negative) — published in The Oncologist (2023), informing Chinese clinical practice guidelines. Visiting Scholar, Cancer Center, Massachusetts General Hospital (MGH) / Harvard Medical School, USA — breast oncology and cancer biology. International research training at Harvard/MGH and Duke University — dual-fellowship expertise in translational and clinical breast oncology.